Status:
UNKNOWN
Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19
Lead Sponsor:
University Hospital, Tours
Conditions:
Certain Disorders Involving the Immune Mechanism
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The pandemic associated with the SARS-CoV-2 coronavirus has affected over 760 million individuals worldwide, resulting in more than 6.9 million deaths. France has also been heavily impacted, with over...
Detailed Description
SARS-CoV-2 is initially responsible for an airborne infection of the upper respiratory tract which, on reaching the lungs, causes a severe acute respiratory illness known as COVID-19. The organism's ...
Eligibility Criteria
Inclusion
- ≥18 years old
- Participant affiliated with a social security scheme
- Participant willing to take part in the study and having provided consent
- Participant in good health or with a stable chronic condition for more than 6 months
Exclusion
- Contraindication for nasopharyngeal sampling
- Pregnant or breastfeeding women
- Participants benefiting from a legal protection measure as referred to in articles L1121-5 to L1121-8 of the Public Health Code (guardianship, trusteeship, etc.)
- Participant with an acute condition unrelated to SARS-CoV-2 infection
- Participant with an unstable chronic condition
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06142279
Start Date
November 1 2023
End Date
November 1 2024
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Tours
Tours, France, 37044